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LONG TERM ANTICOAGUIANT THERAPY AFTER 
ACUTE MYOCARDIAL INFARCTION 
·A Review of the Literature 
.By: Brent E. Krantz 
February 3, 1969 
INTRODUCTION 
LONG TERM ANT ICOAGUIANT THERAPY AFTER 
ACUTE MYOCARDIAL INFARCTION 
A Review of the Literature 
The purpose of this review is threefold: (1) to present the views 
and studies; (2) to elucidate the results of the studies; and (3) to 
present the difficulties in performing the investigations. Many dif-
ferent aspects can be discussed, and certainly separate dissertations 
on some of these aspects could be written. This paper will avoid 
detailed tangential discussions. 
In 1947, Nichol and Fasset (1) described the favorable use of Dicum-
arol for long term anticoagulant therapy in five patients following acute 
myocardial infarction.. They could not know at that time the great con-
troversy they began. Since this initial paper, a multitude of views have 
been presented in the world's literature and conferences. Long term 
anticoagulation after acute myocardial infarction has been a difficult 
treatment to evaluate adequately and accurately. Even after twenty-one 
years of research and discussion, no agreement as to the use of the long 
term therapy has evolved. 
Few of the many investigations have been well controlled for the 
reason that there is an inherent difficulty in selection of patients and 
controls, and further, because of a prevailing attitude during the first 
decade of this research that non-use of long term anticoagulants after 
myocardial infarction might constitute malpractice. During the past 
eleven years, however, evaluation has improved with several well exe-
cuted prospective studies such as those by Bjerkelund (2), Aspenstrom 
and Korsan-Bengsten (3), Manchester (4), The British Medical Research 
-.------~----------------
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Council Report (5), Borchgrevink: (6), Seaman (7), MacMillan, et. al. (8), 
Harvald, et. al. (9), Lovell, et. al. (10), Veteran's Administration 
Hospital Cooperative Study (11), and most recently, Loeliger (12). 
While other less satisfactory studies and opinions are discussed in this 
paper, the above mentioned investigations will be considered in the most 
detail. 
COMMONLY USED AGENTS IN LONG TERM ANTICOAGULATION 
To discuss in detail the pros and cons of the various anticoagulant 
agents is beyond the scope of this paper. However, the pharmacology, 
according to Drill (13) and Goth (14), of the commonly used agents is 
briefly described. 
Heparin is the only parenteral anticoagulant that has been used 
clinically in long term post-myocardial infarction therapy. Heparin has 
essentially three effects on the blood clotting mechanism: 
1. Inhibition of conversion of prothrombin to thrombin. 
2.. Antithrombin effect with the presence of a yet to be identified 
plasma. cofactor. 
3. Depression of the agglutination of platelets. 
Heparin apparently facilitates clot resolution by preventing extension 
of an existing intravascular clot. No evidence of fibrinolytic activities 
has been reported. 
Heparin is not absorbed from the gastrointestinal tract and reports 
of sublingual absorption have not been confirmed. Intramuscular injection 
in ten milligrams per milliliter concentration has been observed to be 
painful locally, while one hundred milligrams per milliliter concentra-
tions have not. Subcutaneous administration is frequently used in dosages 
similar to intramuscular injections. A gelatin dextrose preparation is 
used for repository injections, which is important to long term anti-
coagulant therapy. Intravenous administration is generally used in a 
hospitalized patient because of better maintenance of therapeutic clotting 
times. 
Overdosages of heparin frequently result in hemorrhage. IDng term 
use is frequently associated with osteoporosis. If an antidote for the 
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former reaction is needed, toluidine blue and protamine sulfate are the 
drugs of choice. 
Twenty to twenty~five per cent of the drug given in a single dose 
is excreted in the urine. The remainder is metabolized by liver heparin-
ase and possibly a yet to be identified blood heparinase and is taken up 
by mast cells. MOre will be said about the use of heparin in long term 
anticoagulant therapy after myocardial infarction. 
Coumarin compounds apparently act as depressors of liver formation 
of Factors VII, IX, X, and prothrombin_ This is possibly due to enzymatic 
competition with vitamin Kl- Bishydroxycoumarin (Dicumarol) is the oldest 
of the coumarin derivatives and has been used in many studies of long term 
anticoagulation. Newer drugs with different efficacies are: biscoumacetate 
(Tromexan), sodium warfarin (Coumadin), and cyclocumarol (Cumopyran). 
Since the dosages of these drugs must be regulated by laboratory control, 
no definite dosages can be described here. The slow action, the variable 
absorption from the gastrointestinal tract, and the variable metabolism 
among individuals who use Dicumarol, are the reasons why so many substi-
tutes have been synthesized. 
Coumarin drugs are all administered orally. Coumadin, however, may 
be used parenterally although it is not frequently dore. FolloWing the 
administration of coumarin drugs, a latent period results because of the 
necessity of clearing Factors VII, IX, X, and prothrombin from the blood. 
Following discontinuance of the drug, the drug is cleared from the body 
in one to eight days. Metabolism of the coumarin compounds in the liver 
is believed to be fairly complete since very little is observed in the 
liver unchanged. 
The main toxicity of the coumarin drugs is hemorrhage which can be 
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treated with vitamin Kl - The effect of this vitamin occurs within one-
half hour. 
Inandione compounds have been used in several long term therapy 
studies. Their action is believed the same as coumarin oompounds. The 
principle preparations are phenindione (Hedulin; Danilone) and diphenadione 
(Dipaxin). Phenylindandione has been used and is now available. As with 
the coumarin drugs, the dosages must be regulated by laboratory oontrol. 
Although there have been case reports of granulocytopenia and 
jaundice-producing liver disease with the inandiones, this probably repre-
sents hypersensitivity rather than toxicity. Polydipsia, polyuria, and 
tachycardia as well as overdosage and subsequent hemorrhage are the 
toxicities of these drugs. Vitamin Kl can be used as an antidote for 
the hemorrhage, but higher dosages must be used than for coumarin oom-
pounds. 
In summary, the inandiones and coumarin compounds have similar 
mechanisms of aotion, while heparin has a different one. In theory, the 
end result should be the same, both preventing clot formati on or at 
least extension of an existing clot. Results of studies using these drugs 
will be presented. 
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THE FIRST DECADE (1947-1957): OPl'IMISM WITHOUT CONFIRMATION 
Nichol and Fasset (1) reported five patients who were followed for 
six to thirty-two months on long term Dicumarol therapy after an acute 
recurrent myocardial infarction. One of the patients died while he was 
"inadequately anticoagulated", but the other four patients suffered no 
ill effects. This study, done in 1947, began the era of long term anti-
coagulant therapy after myocardial infarction. 
Three years after his initial report, Nichol teamed with Borg (15) 
and added seventy-three patients to the original five. This report was 
also favorable to the use of long term anticoagulant therapy and indi-
cated its feasibility in spite of the variability of the Dicumarol require-
ments, as determined by the Quick one-stage prothrombin test. The fact 
:jhat the therapy was feasible did not deter tm authors' opinion "that 
the therapy was much trouble for both the patient and the physician". 
The third report, in 1954, by Nichol and his associates (16) included 
two hundred ninety-five patients between the ages of thirty-three and 
eighty-three years. One hundred twenty-nine patients continued therapy 
while the remainder dropped out for various reasons including death, 
hemorrhage, and loss of interest and willingness to co-operate. Of tm 
patients who discontinued the study, thirty-seven deaths occurred from ten 
days to three years after therapy was stopped. 
Hemorrhage was frequent, seventy-three patients having developed 
hemorrhagic complications. The results of this study prompted Nichol to 
conclude, "Hemorrhage must be accepted as a calculated risk when embark-
ing on long term anticoagulant therapy and weighed against the results to 
be derived." This statement holds true today, if one accepts long term 
anticoagulant therapy as beneficial after myocardial infarction. However, 
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at the time of this statement, TiO one had conducted a prospective study 
with controls; this made such a statement L~ 1954 prematuree Perhaps 
this opinion reflected the consensus at that time that long term therapy 
was sound treatment and that its omission bordered on malpractice. 
Foley and Wright (17) and Scott (18) wrote in separate small studies 
about the feasibility of long term anticoagulant therapy after myocardial 
infarction. The former emphasized the necessity of one-stage Quick 
prothrombin determinations every seven to fourteen days, while the latter 
recommended determip~tions each week. Hemorrhages were frequent compli-
cations in both studies, but no deaths were attributed to hemorrhage. 
Owren (19), Lund (20), and Muri (21) reported separate studies using 
long term Dicumarol therapy in small groups of thirty-seven, fourteen, 
and sixty-seven patients, respectively, who were followed with the PP 
prothrombin-proconvertin determination. Results indicated that when the 
PP values were within the ten to thirty per cent therapeutic range, the 
treatment '-las valuable prophylactically. Fortunately, the treatment 
was feasible with good physician, laboratory, and patient co-operation. 
These studies were uncontrolled and too small to make valid conclusions. 
Ll'J.deed, for want of controls, Muri compared the results of his study 
favorably with other studies which investigated prognosis following 
myocardial infarction in other countries during a different time period. 
Olwin (22) reported on the control of long term anticoagulant therapy 
with Dicumarol using a two-stage prothrombin determination. Bleeding 
occurred in Honly fifteen per cent n of his small series and this was 
treated with vitamin K administration and discontinuance of therapy. He 
felt that the two-stage method allowed mer e accurate follow-up of therapy 
compared with the one-stage Quick method. Many different tests for the 
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determination of prothrombin levels have been developed, each with its 
proponents. The Quick one-stage method has been used mostly in the 
United States, whereas, PP determinations and thrombotests have been 
used principally in Scandinavia and other European countries during the 
past fifteen years. 
In 1953, Keyes, ~. ~. (23) published their first report on a 
restrospective study with "two comparable groups with myocardial in-
farction". Long term therapy was defined as that continuing beyond six 
weeks. The majority of the patients were followed from one to two years. 
The patients were treated with long term Dicumarol for the following 
reasons: (1) continuation of refractory angina pectoris after recovery 
from myocardial infarction; (2) survival of a recurrent myocardial 
infarction; and (3) development of coronary insufficiency suggesting 
impending coronary occlusion following an asymptomatic post-infarction 
period. The therapy was regulated with the use of the one-stage Quick 
prothrombin determination. The treated group of sixty-three patients 
was much smaller than the one hundred forty-seven patients who served as 
controls. The controls were selected from patients treated for ~ocardial 
infarction prior to the era of long term anticoagulant therapy. The 
results were markedly in favor of long term anticoagulant therapy as to 
reinfarction and mortality. Hemorrhage occurred in ten per cent of the 
patients treated and one death was attributed to the anticoagulation. 
The authors emphasized the recurrence of myocardial infarction in seven 
patients who stopped therapy shortly before the episodes. As can be 
seen, this study is open for bias because of the inequity in the size of 
the control and treated groups, as well as the bias inherent in retro-
spective studies. 
-9-
In 1956, Keyes and his associates (24) divided the patients into 
single and multiple infarction groups. Each of these was subdivided 
into treated and control groups. The single infarction group of two 
hundred fifty-seven patients was divided into the treated group of 
seventy-one patients with recurrent coronary pain or failure, and the 
control group of one hundred eighty-six patients who were without re-
current symptoms. In the recurrent infarction group, the controls 
(forty-eight patients) were those who had been treated prior to 1946 and 
the advent of long term anticoagulant thereapy; the treated group (fifty 
patients) were those who had their myocardial infarctions after 1946. 
The results were very favorable for long term anticoagulant therapy, 
since only nine per cent of all treated patients died as opposed to 
forty-one per cent of the control patients who succumbed. Hemorrhage 
occurred frequently in spite of the therapy controlled by the one-stage 
Quick method. In fifty-one patients, there were fifty-four episodes of 
hemorrhage, but no deaths occurred. However, the authors felt that the 
benefits of therapy outweighed the disadvantages. The same criticism 
which was made for the 1953 study by Keyes holds true. 
In 1956, Tulloch and Wright (25) studied the use of Dicumarol in 
treating many types of thromboembolic disorders including thirty-five 
myocardial infarctions in thirty-two patients. The one-stage Quick method 
was used to keep prothrombin times between twenty-five and thirty sec-
onds. Five t'hromboembolic episodes occurred during treatment with two 
deaths. There were seventy hemorrhages in forty-three patients in the 
entire series. When prothrombin times were available, they were found to 
be frequently less than twenty seconds with the thromboembolic episodes 
and greater than forty seconds with the majority of the hemorrhages. 
This study also emphasized the feasibility of long term anticoagulant 
-10-
therapy with adequate control of prothrombin levels. The conclusion is 
similar to previous investigations which have been favorable to long 
term anticoagulant therapy. However, since no controls were described, 
the study is invalidated from the viewpoint of effect of therapy on 
recurrence of thromboembolic phenomena. 
Owren (26) reported a second series of 700 patients of which two 
hundred thirty-four were post-myocardial infarction patients who were 
treated with long term (eight weeks or more) Dicumarol therapy and con-
tinually evaluated with the prothrombin-proconvertin test at levels of 
ten to thirty per cent determined at one to three week intervals. Both 
daily maintenance and intermittent dosages were used and evaluated with 
the former proving to maintain PP values in the therapeutic range more 
effectively. This study also indicated decreased mortality and decreased 
reinfarction rates, but without controls. The principle value, like the 
previous studies mentioned, was the indication of feasibility of long 
term therapy. 
In a retrospective study, Bay (27) also investigated a small number 
of patients (sixty-eight) treated with long term anticoagulant therapy 
after myocardial ir~arction. He found a mortality rate of three and 
one-half per cent and hemorrhagic complications in ten and one-half per 
cent of the patients. Bay concluded from his study that the value of 
anticoagulation ceased to improve the reinfarction rate after two to 
three years and that it might be advantageous to stop therapy at that 
time. This was the first study to suggest the discontinuance of therapy 
after a certain period of time. However, lack of a control again deterred 
from the study. Nany authors have emphasized the discontinuing of therapy 
after variable periods of therapy and these will be discussed later. 
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Foley, at. aI., (28) described two groups of eleven and twelve 
patients who were treated for a total of five hundred ninety-seven 
months and five hundred fifty-four months, respectively, with long term 
post-myocardial infarction Dicumarol therapy controlled by Quick's one-
stage method. The first group were patients with more than one previous 
infarction and the second group with just one infarction. The results 
indicated that therapy should be instituted in recurrent infarctions, 
in prominent episodes of congestive heart failure, and when multiple 
embolic episodes have occurred. Hemorrhage did not seem to be a problem 
since there were only thirty-one episodes in eight year s. Unfortunately, 
this study, like many others, was without controls. 
Engelberg (29) introduced long term intermittent subcutaneous 
.;,,1; 
heparin therapy in two hundred patients with myocardial infarction~ 
Efforts to control the study included a treated and control group of fair 
comparability as to age and sex, but without other comparisons. Therapy 
was extremely successful in terms of difference in mortality with twenty-
one per cent in the control group and four per cent in the treated 
group. This optimistic report with at least a token control group was 
the only study done with long term heparin in the 1947-1957 decade of 
therapy. This study marks the first one in the literature that was 
carried out in a prospective manner. Further discussion of long term 
heparin therapy will follow in the section which discusses the period, 
1958 to the present. 
Returning to oral therapy with Dicumarol, Suzman, ~. ll- (30) 
divided two hundred eight patients into three groups: eighty-eight in 
the "short termfl control group treated three months or less; eighty-two 
in the "long terml1 group treated from three to seventy-six months; and 
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thirty-eight in the group of dropouts who had been under therapy for 
three to thirty months.. As usual for the American studies, the Quick 
one-stage prothrombin time determination was used for regulation of 
therapy. The comparability of the two principle groups, "short term" 
and "long term", was fairly good; however, the main drawback of the 
study was that lithe decision for the patients' participation was left 
entirely up to the patient ll • Selection by this method allows economic 
considerations to be important and thereby produces bias. The differ-
ences in mortality and reinfarction rates seem statistically significant 
in favor of long term anticoagulant therapy--twenty-nine deaths and 
twenty-four reinfarctions in the "short term" group and six: deaths and 
seven reinfarctions in the "long termll group. Other differences in the 
two groups were not significant. They did consider the history of pre-
vious infarction and concluded that from their investigations that mild 
and uncomplicated cases, whether treated or not, had a favorable prognosis 
in contrast to the substantial mortality rate found in severe or compli-
cated cases. However, in contrast, the patients most likely to benefit 
from long term anticoagulant therapy were those in whom the presenting 
attack was severe and there had been a previous myocardial iP1arction. 
In a later article, Suzman (31) acknowledged tIe need for further well-
controlled prospective studies for establishing or disestablishing the 
treatment. 
Manchester (32) studied seven hundred twelve patients who were 
divided into a treated group taking Dicumarol and ascorbic acid and a 
placebo group taking ascorbic acid only.. Four hundred four patients 
remained in the study after ten years and one hundred fifty-seven patients 
who were taking no medication were followed. This group was called the 
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untreated or Ilcontrol" group_ The inclusion of the "controll! group 
destroyed any comparability that the three groups may have had in addi-
tion to disallowing random selection. Upon finding eight times greater 
mortality in the untreated and placebo groups, Manchester acknowledged 
the advantages of the Dicumarol treatment. He also suggested that 
ascorbic acid may decrease the fragility of the vessels and aid in the 
therapy. He emphasized that in spite of the many favorable studies on 
the long term anticoagulant therapy, including his own, the therapy must 
be individualized to meet the demands of the patient. 
In 1957, both Tanzi and Van Ness (33) and Owren (34) presented uncon-
trolled studies on the use of long term Dicumarol and phenindandione, 
respectively. Typically, the American investigation was controlled by 
the Quick one-stage prothrombin tL~e and the Scandinavian study with the 
PP determination. Both studies compared their series with other studies i 
done at different times and places, and the results were typically favor-
able. 
A preliminary report on the long term use of Dicumarol with PP value 
control after myocardial infarction was presented by Aspenstrom and 
Korsan-Bengsten (35). Fifty-seven patients were followed, including 
twenty-eight IIgood risk" and twenty-nine "poor risk" patients using the 
criteria by Brof~~. al. (36) for classification. Seven patients, 
two in the former and five in the latter group, died. No fatalities were 
ascribed to the therapy. Although few patients had been studied, the 
investigators believed that patients who were stress hyperreactors (persons 
so classified in regard to their blood coagulability) would achieve the 
most benefit from the drug. They conceded the need for much more study 
to prove their hypothesis. 
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Finally, ten years after the initial report on long term anti-
coagulant therapy after myocardial infarction, an excellent prospective 
study with random selection of the patients was reported by 
C. J. Bjerkelund (2). Bjerkelund believed that most of the studies pre-
viously done were concerned more with feasibility and practicality of 
long term therapy and not with the results of the treatment. In the 
previous studies discussed in this paper, this is true with the notable 
exceptions of the Suzman and, Manchester studies. Bjerkelund was the 
first to emphasize the factors of pathogenesis of coronary occlusion. 
He stated that thrombosis had been commonly known to occur in only fifty 
per cent of the myocardial infarctions. He believed that this fact 
established theoretical limitations to long term anticoagulant therapy. 
Two hundred seventy-seven consecutive patients under seventy-six 
years of age who survived thirty days following an acute myocardial 
infarction were randomly appointed to a treated group and control group 
in Bjerkelundts study. Forty patients were excluded from therapy for 
similar reasons in both groups. Finally, one hundred nineteen patients 
were treated with anticoagulant therapy, while one hundred eighteen 
patients were in the control group. Detailed statistical analyses were 
applied to the control and treated groups and no significant differences 
at the five per cent level of statistical significance were found in any 
of the compared factors, including the treatment during the acute phase 
of the myocardial infarction. Anticoagulation was controlled with PP 
determinations and values less than thirty per cent were found in eighty-
two and one-half per cent of the determinations, and less than forty per 
cent in ninety-two and three tenths per cent of the PP values for the 
treatment period. Generally, PP values of ten to thirty per cent were 
considered to be in the therapeutic range. According to Bjerkelund, an 
-15-
analysis of PP values near the time of reinfarction and death in thirty-
one patients revealed that a relative reduction in the intensity of 
treatment could not have played an important part in causing these 
episodes. 
The mortality rate of patients under sixty years of age who had 
been treated with anticoagulants for the first twelve months of therapy 
was less than the control group, and this difference was statistically 
significant at the five per cent level. Although the trend of the study 
was in favor of the use of anticoagulants, this result was the only one 
that assumed statistical significance at the five per cent leveL How-
ever, when the patients of all ages were compared as to modes of life, 
ability to work, and morbidity, the study revealed that morbidity was 
great1er in the control patients who were admitted to the ho~pital more 
often and stayed longer than the treated patients. 
Hemorrhage occurred once in every seven and nine-tenths patient-
years of treatment. If only the moderate and major hemorrhages are in-
cluded, occurrence was once in every thirteen and one-tenth patient 
years of treatment. Four of these hemorrhages were fatal cerebrovascular 
accidents. 
In previous studies treatment had been especially indicated for 
patients with recurrent infarction and in those myocardial infarction 
cases with a tendency to heart failure and thromboembolic episodes. 
Bjerkelundts study presented evidence that showed that the major benefit 
was primarily in the younger patients who had had only one infarction8 
This seems reasonable when one remembers that the treatment is pri-
marily prophylactic and not curative. Therefore, according to this 
study, long term therapy seems to be indicated primarily for the "good 
risk" cases. 
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Thus, with the exception of ffjerkelund's study (2), investigations 
during the first ten years of treatment for myocardial infarction by long 
term anticoagulant drugs demonstrated the feasibility of the treatment 
much more than they proved the scientific significance of the treatment 
itself. 
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THE SECOND DECADE (1958 to the present): IMPROVED IWJESTIGATION WITHOUT 
GENERAL AGREEMENT 
The second decade, like the first, has been marked with studies 
which have continued to emphasize feasibility rather than effectiveness 
of therapy. Most of these studies were early in the decade. 
Eisenstadt (37), Wrage and his associates (38), Loughridge (39), 
Nora (40), Swan (41), and Pollard with his associates (42) described the 
care of s~all numbers of patients for varying periods on oral anticoag-
ulants in each of their papers. Even in 1965, Reinberg and Lipson (43) 
reported a series of one hundred eighteen patients followed for eight 
years with thrombotest and PP determinations. Though the conditions 
of the studies were different, the conclusions were the same: that long 
term oral anticoagulant therapy is feasible, practical, and effective in 
preventing thromboembolic episodes. One cannot argue that the long term 
therapy is not feasible and practical, but the conclusion in regard to 
effectiveness of the therapy must be reserved for more detailed and well-
controlled studies. 
Seaman (44) has described three factors that govern feasibility. 
First, the therapist must be experienced and thoroughly familiar with the 
particular anticoagulant selected. Second, a dependable laboratory method 
of assessing control must be available. Finally, the patient must be 
reliable, fully informed of the necessity of his co-operation and aware 
of the risks, both of his disease and of the therapy. The first two 
factors must be available before anticoagulant therapy can even be pre-
sented to the patient. If they are, there is less chance of complication 
and perhaps increased value in the therapy. 
Fewer retrospective studies appeared during the second decade. 
Odegaard (45), Connel and Mayer (46), Lund-Johansen (47), and Roysten (48) 
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reported studies done in retrospect. As had been true of previous, 
similar studies, success with long term anticoagulant treatment after 
myocardial infarction Vias noted. Roysten emphasized that a case should 
be in the therapeutic anticoagulation range at least eighty-five per cent 
of the time in order to render treatment effective. He felt that the 
effectiveness of the therapy had been proven by his study and others, 
and believed that future investigation should concentrate on the degree 
of control of prothrombin levels. 
Toohey (49) l~~dertook a careful retrospective study, but took 
control patients from the period preceding long term anticoagulant 
therapy as well as patients who were more severely ilL The decrease 
in mortality and reinfarction rates were striking compared to the control 
group, and because the patients who were treated were more severely ill, 
Toohey believed that this strengthened the case for the use of anti-
coagUlants. 
Nichol, st. aL (50) reported a composite study compiled by ITlany - -
investigators from many different areas consisting of 1091 patients. 
HControlsll were those patients vJho discontinued therapy after three to 
eighty months of therapy. DicTh~ro1 and C1Xffiopyran were used, and the 
one-stage Quick test was employed to evaluate the prothrombin levels. 
}1'a.rked differences between control and treated groups suggested not only 
the value of the therapy, but the presence of a !!rebound phenomenon"" 
The patients who discontinued therapy abruptly seemed to be more sus-
ceptib1e to reinfarction than patients who continued therapy$ There 
were twenty deaths in the first month after having stopped therapy. 
Hemorrhage occurred in hlenty per cent of the patients il>iho were treated. 
Ensor and Peters (51) presented a study of two hQ~dred sixty-eight 
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patients who had been treated prophylactically after myocardial infarc-
tion. Patients who had discontinued therapy were called Itpseudocontrolsl! e 
After five years, the mortality rate of the treated group was twenty-one 
per cent as compared to twenty-nine and three-tenths per cent of the 
"pseudocontrolsll, and forty-four and two-tenths per cent of a control 
group taken from the literature. Both the Nichol study (49) and the 
Ensor and Peters study used withdrawals from therapy and called them 
"controls tl and tlpseudocontrolslt, respectively, using the quotation marks 
in recognition of the low control value these groups represented. 
Thomes and his associates (52, 53) presented two papers indicating 
favorable results using anticoagulant treatment on patients with thrombo-
emoblic phenomena, but did not describe their results with myocardial 
infarction patients. However, they felt that it was important to remember 
that if long term anticoagulants did improve prognosis and prolong life, 
controlled studies would be difficult after a short period of time because 
of the accumulation of "poor risk" patients in the treated groups. 
K~1n, ~. ~. (54) carried out an investigation for nine years of 
long term Dicumarol therapy following myocardial infarction with the one-
stage Quick prothrombin test used to evaluate prothrombin levels. As 
with other retrospective studies on this subject, there was no randomi-
zation. However, withdrawal patients were not placed in a "control" 
group as in the previous studies by Nichol (50) and Ensor and Peters (51). 
The study indicated a favorable de.crease in reinfarction and mortality 
rates, comparing well with other studies. Kuhn felt that the occurrence 
of hemorrhage in only eleven per cent was well within the limits of toler-
ation when compared with the effectiveness of therapy. 
In the first decade, 1947-1957, few papers were written about the 
control of therapy and the true therapeutic clotting factor levels that 
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would produce fewer hemorrhages and fewer thromboembolic episodes. Most 
authors have commented about the type of laboratory study used and the 
factor levels which were believed to be therapeutic. Following are 
several studies on control of therapy which are appropriate because of the 
increasing number of well-controlled prospective studies. 
Hjoit and Molne (55) studied forty-five patients who had an average 
thrombotest value of twenty-three and nine-tenths per cent before rein-
farction and upon admission to the hospital, after reinfarction, the average 
values were twenty-nine and four-tenths per cent. Although the differ· 
ence between these two values seems statistically significant, the differ-
ence is too small to justify conclusions that recurrent infarction is 
usually caused by "escape" from anticoagulant therapy. However, Molne 
and her associates (56) later related the level of anticoagulation with 
autopsy findings after death. On final ad-mission to the hospital, PP va.lue 
or the thrombotest was determined. The group of patients with coronary 
thrombosis and myocardial infarction had a mean prothrombin content of 
thirty-two and three-tenths per cent while those with only myocardial 
infarction had a mean prothrombin content of twenty-four and seven-tenths 
per cent. They concluded that adequate anticoagulant therapy may afford 
some protection against coronary thrombosis. 
Bjerkelund (57) concurred and stated that episodes of reinfarction 
and sudden death occurred with PP values that were statistically in agree-
ment with the PP level during the total period of treatment in his study. 
He concluded that rises in the PP values above the therapeutic range were 
not responsible for these episodes. It must be remembered, however, that 
many factors including stress, reinfarction, concurrent illness, drugs, 
and changes in emotion may vary the PP value or thrombotest value. 
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Therefore, one cannot prove by either of these studies that infarction 
occurred when the prothrombin ranges were in "therapeutic ranges"~ 
Owren (58) described the importance of Factor X in regulating 
anticoagulant therapy. He stated that the thrombotest was the only one 
of the commonly used tests that measured this factor, and, therefore, was 
the best test for anticoagulant therapy control. The bleeding complica-
tions produced by "too intensive" therapy were all associated with a 
Factor X level below five per cent. 
Moschos and his associates (59) derived an investigation to deter-
mine prothrombin concentrations in which there were the fewest hemorrhages 
and thromboembolic complications. Four types of laboratory tests were 
used, the one-stage method of Q~ck, the one-stage method of Owren, and 
near the end of the study, the PP determination and the thrombotest. One 
hundred seventy-eight patients were divided into the intensive (ten per 
cent to twenty-five per cent of normal), moderate (thirty per cent to 
fifty per cent of normal), and control (greater tr~n sixty per cent of 
normal) groups. In this study, moderate therapy was the best because the 
sum of the risk of complication and the risk of hemorrhage were least. 
Two years later, MOschos (60) presented a follow-up of the original 
patients and concluded that moderate anticoagulation remained the best 
therapy even though this was not proven conclusively by the study. 
Borchgrevink (6) preceded the Moschos study, but had two groups with 
high degree of comparability. His study included patients with myocardial 
infarction, angina pectoris, or both. He divided his patients randomly 
into the intensively treated (twenty per cent PP value), and moderately 
treated (fifty per cent PP value). He declined the use of a control 
group because he felt there was a previous L~dication of therapeutic 
necessity. Pheni.'r1dandione was used as the anticoagulant agent" The 
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differences between the two groups were significant as to mortality and 
reinfarction with the intensive group showing better results than the 
later study by MOschos (59, 60). Both studies were without control groups 
which detracted from their conclusions. 
Since the Borehgrevink study supported intensive treatment and the 
:r.1oschos study supported moderate treatment, another study was needed. 
Loeliger, et. al. (12) used the thrombotest and found intensive therapy - -
(five per cent to twelve per cent of normal) to be effective, whereas, 
moderate hypocoagulability (twelve per cent to twenty-five per cent of 
normal) was of limited or no value. Loeligerfs study is one of the most 
recent well-controlled, double blind, randomized trials in the literature 
on long term anticoagulant therapy after myocardial infarction. Phen-
procoumon was the agent used~ The difference in the rate of cardiovas-
cular deaths was not significant between the treated group (four and 
eight-,tenths per cent), and the placebo group (seven and t~tenths per 
cent). The difference in the two groups as to reinfarction was much more 
obvious (treated, one and two-tenths per cent to the placebo, eight and 
seven-tenths per cent) and of high statistical significance. The main 
fear of therapy with this intensity is hemorrhage. In Loeliger1s study, 
hemorrhage occurred once in every ten patient-years of treatment. Thus, 
we have cited three good studies which have investigated, specifically, 
the intensity of treatment. The most convincing papers suggest that high 
intensity therapy is the most valuable~ 
The achievement of therapeutic levels described in these studies are 
easily taken for granted upon reading them in the literature. However, are 
therapeutic levels easily obtained L~ practice? Hutton (61) reported a 
study in which less than fifty per cent of the patients who had been 
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treated with oral anticoagulants by a hospital house physician, were well-
controlled in their therapeutic levels. 
The study of the Working Party on Anticoagulant Therapy in Coronary 
Thrombosis of the British Medical Research Council (5) in 1959 was the 
first major investigation published in the second decade. It was con-
ducted because there had been few good studies prior to that time. The 
patients were divided into groups according to their number of infarctions, 
and then these groups were randomly divided into "high and low dosage" 
sub-groups. Phenindione was given in therapeutic dosages to the high 
dosage group to keep the one-stage method of Quick at two and one-half 
ti.nes normal. The "low dosage" group was given one milligram of phen-
indione which was not enough to affect the prothrombin time. The death 
rates showed the "high dosage!! group to be better than the "low dosage" 
group but not with statistical significance. However, in patients under. 
fifty-five years of age, the reinfarction rates in the "high dosage" 
group were one-fifth that of the "low dosage" group which is statistically 
significant. Although the risk of reip~arction was more improved by high 
dosage regime in patients with previous history of myocardial infarction, 
there was no statistically significant difference. It was apparent to . 
the investigators that the patients on the high dosage returned to work 
during the treatment years more frequently than patients on the low dos-
age. Both Arnott (62) and an article in the British Medical Journal (63) 
reviewed and summarized the BMRC study favorably. 
A follow-up of the BMRC report (64), published in 1964, showed no 
significant changes from the earlier report. However, the report pointed 
out that the use of anticoagulant therapy reduced the reinfarction and 
mortality rates decreasL~gly for up to two years post-infarction, compared 
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to Bjerkelund's report (2) that after twelve months, little benefit 
resulted. 
McMichael (65) reviewed the Bi~C report and took issue with its 
conclusions and defined the following flaws in the method. Instead of 
the B~~C'S concept that long term therapy began after twenty-nine to 
forty-three days, he proposed three months as the upper limit of short-term 
therapy because in his opinion, studies have shown that after three 
months, little L~provement in mortality or morbidity rates is gained. 
Since reinfarctions are so difficult to diagnose and many of the rein-
farctions were so benign, he questioned the validity of the diagnosis 
and,therefore, the conclusion that anticoagulant therapy aided the treated 
patients in this respect. He attacked the division of the patients as 
to age and sex after the study was completed instead of prospectively. 
The risk of hemorrhage in the study was ten per cent, which in McMichael'l s 
opinion did not counterbalance the small value of therapy. McMichael 
suggested the following paragraph as the concluding one of the study 
instead of the favorable one that actually ended the study. 
"If one hundred patients were treated for two years after the acute 
phase (three months) was over, there would probably. be no difference in 
mortality from a control untreated series. The untreated patients may 
have more disquieting episodes of chest pain, but these will neither 
increase the mortality nor the disabling consequences of myocardial 
necrosis. On the other hand, the treatment even in first class centers 
is difficult to control and supervise. Serious, or even fatal bleeding 
may occur in ten per cent of the cases: death and disability from cere-
bral hemorrhage are real risks. Further, those who die of the treatment 
are not necessarily those who would have died without it. The regime 
thus involves human sacrifice for a very dubious gain. An effective 
prophylactic regime against thrombosis should continue to work and not 
suddenly cease to be effective at the end of two years: any other con-
clusion is not logicaL Therefore, the long term ,:use of our present 
anticoagulants for coronary disease should be abandoned. 1I 
McMichael t s arguments are valid and convincing. Equally as much 
caution, however, should be observed in the acceptance of negative con-
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c1usions as have been in the acceptance of the positive conclusions. 
Further, it is important to remember that no perfect study has ever. been 
devised. There are most certainly "loopholes" in all investigations and 
one wonders if such an astute critic as McMichael could not rewrite favor-
able concluding paragraphs to many other studies as negative as he has 
done this one. 
In 1961, Manchester (66, 67) reiterated his first study and reported 
a follow-up in 1964. In his follow-up he concluded that the long term 
therapy was more effective in patients under sixty years of age than 
over. He stated that the present results of continuous anticoagulant 
therapy for five to fifteen years offers more for the individual who has 
recovered from a myocardial infarction against the hazards and probability 
of reinfarction than any currently employed medical regime that is avail-
able. The younger the patient, the more imperative is the need for such 
therapy. The critique of the original study applies to this one. The 
further conclusions drawn from the second report are acceptable only if 
one realizes that the follow-up was carried out over a long period of time. 
The many changes in the control and treated groups caused by death and 
withdrawals for many reasons allowed even more variables to enter the study 
to produce bias. 
In 1961, Bjerkelund (68) summarized his previous study as well as his 
follow-up of his original patients. He still believed that treatment is 
primarily indicated in the younger age groups, that it is perhaps not 
worthwhile to continue this therapy more than twelve months after the 
acute attack, and that the effect achieved during the first twelve months 
is not lost after gradual cessation of therapy. 
In 1960, Brown, MacMillan and Watt (8) presented their first report 
on a small group of fifty-eight patients invited to participate in a 
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study of long term Dicumarol therapy after myocardial ip~arction. 
Therapeutic values were considered to be between twenty to thirty seconds 
with the one-stage Quick method of determination. Only fifty patients 
participated in the study because eight patients did not return for follow-
up. They were divided into high and low dosage therapy by chance. The 
results were in opposition to all previous stUdies. The high dosage group 
had greater mortality and reinfarction rates than the low dosage group. 
Their conclusion was that the establishment or disestablishment of the 
therapy had not yet been denied or upheld. A year later, they followed 
their first report with a follow-up which was published in two journals 
(69, 70). They added twenty-one patients to the study and the conclusions 
were unchanged. The main criticisms of this study were the small size of 
the group, the invitation for participation to the patients, and twenty to 
thirty second prothrombin times being considered therapeutic. The first 
two criticisms were acknowledged by the authors. The latter criticism is 
considered in view of the previous presentation of Loeliger's (12) work, 
even though different tests for evaluation were used. The negative results 
of the therapy have been explained by proponents of long term anticoagula-
tion on the basis of the "likelihood" of inadequate therapy. 
In 1961, Conrad, et. al. (71) reported a study of twenty-five patients 
treated with phenprocoumon and twenty-five patients treated with place-
bos. Both groups had been selected randomly and began treatment on the 
twenty-eighth day of post-infarction. The treated patients were controlled 
by the one-stage Quick method. Few of the pat:ie nts in either group had pre-
vious complications. At the time of the study, no difference could be 
found between the two groups as far as mortality and reinfarction rates 
were concerned. 
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Conrad I S second study (72), using the same criteria but with an jn-
creased number of patients, concluded that patients over sixty who had a 
previous histo~J of atherosclerotic heart disease benefitted from the 
prophylaxis afforded by long term anticoagulati on. There were thirty-nine 
bleeding episodes in twenty-three patients. The investigators attributed 
the increased reinfarction rate among the good risk patients under fifty-
five years of age to the increased number of patients who stopped therapy 
because of hemorrhage. The high association with reinfarction shortly after 
stopping therapy has been referred to as "rebound phenomenal!. 
Although many investigators had mentioned an increased incidence of 
thromboembolism shortly after stopping therapy, Carter and his associates 
(73) were the first to study this aspect specifically. They found a 
definite increase in the number of thromboembolic episodes within siX 
weeks after the discontinuance of therapy. They suggested tapering off 
the therapy over a period of several days or weeks. 
Sise (74) did a retrospective study of two hundred thirty-nine 
patients and found that the greatest risk was when the patient discon-
tinued anticoagulant therapy because of bleeding. He postulated that 
the transfusions may cause hypercoagulability because of the clotting 
factors in the transfused blood, that bleeding may accelerate the form-
ation of clotting factors, that vitamin Kl therapy may "overshoot", and, 
finally, that the stasis that results from bedrest in the hospital may 
cause this increased number of episodes8 Sisels second report with his 
associates (75) arrived at much the same conclusion, although it included 
more patients. The authors felt that interruption of treatment for 
reasons other than bleeding was not associated with early thromboembolic 
complications. 
Dinon and Vander Veer (76), Sivertssen and his associates (77), 
and an article in the British Medical Jourr~l (78) discussed the 
Ilrebound phenomenal!, the former two presenting limited investigations. 
Dinon and Vander Veer both ascribed to the gradual tapering off of 
therapy because of the l1rebound", but Sivertssen found no evidence of 
"rebound phenomena". The British ~1edical Journal discussion commented 
on the advisability of resuming anticoagulant therapy after stopping for 
hemorrhage and then discontinuing the therapy over a lengthy period of 
time. 
Van Cleve (79, 80) has presented two good articles on his study of 
"rebound phenomena". Two groups were selected, but not randomly. The 
first discontinued their Coumadin therapy over a six week period; the 
second group stopped anticoagulant therapy abruptly. The results sug-
gested that clinically recognized "rebound thrombosis!! does not occur 
after long term Cou~din treatment. However, the long held opinion that 
patients who stop therapy because of bleeding ~re more susceptible to 
I!rebound thrombosis" was a possible exception to the negative findings. 
In the second study, his results were the same and his conclusion was 
that among the patients selected to stop therapy (all had been treated 
at least three years) the results of the study suggested tr..at "rebound" 
was not a significant problem. 
To continue with the prospective studies on long term anticoagu-
lation after myocardial infarction, Harvald, Hilden, and Lund (9) reported 
a series of three hundred fifteen patients who were observed from five 
to seven years in a well-controlled study. The one hundred forty-five 
patients who were treated were given Dicumarol or phenprocoumon and con-
trolled by the PP determination. The one hundred seventy patients in 
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the control group were given placebos. The PP values were in the 
therapeutic range in eigh~five per cent of the determinations. The 
groups were comparable as to age, sex, and risks. Although the results 
showed a trend toward decreased mortality and reinfarction rates in the 
first year among the treated patients, the only statistical difference 
was in the reinfarction rate of patients over sixty years of age. This 
is siIDilar to the findings of Conrad (71, 72). No "rebotmd phenomena" 
were discovered in this study. Harvald stated that as matters stand 
today, it does not seem justifiable to advise anticoagulation as a 
routine after myocardial infarction. It is at this time impossible to 
describe which patients should get the drug, let alone the duration of 
the treatment. The need for anticoagulants cannot be ruled out after 
myocardial infarction, but the present study has shown no great benefits 
to the prophylaxis of the disease~ 
Seaman, ~ • .e.1~ (81) presented a preliminary report of a double-
blind study with three groups of patients allocated randomly: those with 
phenindione, those with placebo, and controls. The former two groups 
were treated alike and seen at least every four weeks, while the controls 
were seen every six months. PP determinations were used to evaluate 
the therapy using twenty per cent levels as therapeutic. At tie time of 
the first report, no advantages were found in anticoagulant therapy in 
regard to mortality or reinfarction rates. 
The second report (7) a year later L~dicated no statistical signi-
ficant differences between the three groups, but stated that the anti-
coagulated group spent more time in the hospital than the other two. 
No I1rebound phenomena" were recognized in this study. The investigation 
was well conducted with three comparable groups. The double-blind method 
and its inherent ability to decrease bias is an aid to most stUdies v/hich 
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are otherwise well conducted. Loeliger (12) ~rould argue tr~t the twenty 
per cent PP level is not within the best therapeutic range and, therefore, 
the positive effects of the treatment are lost. 
Aspenstrom and Korsan-Bengsten (3) conducted a double-blind study 
of Dicumarol prophylaxis after myocardial infarction. They found no 
significant differences in the over-all mortality rate, but they did find 
significant differences in the number of fatal reinfarctions, the anti-
coagulated group having fewer. The striking difference in this study was 
between good and poor risk patients. The poor risk patients were class-
ified under Russek's criteria (82) as listed here: 
1. Previous L~farction 
2. Intractable pain 
3. Extreme degree or persist~nce of shock 
4. Significant cardiac enlargement 
5. Gallop rhythm 
6. Congestive heart failure 
7. Atrial fibrillation or flutter, ventricular 
tachycardia, or intraventricular block 
8. Diabetic acidosis, marked obesity, previous 
pulmonary emboli, varicosities of the lower 
extremity, thrombophlebitis, or other states 
predisposL~g to thrombophlebitis. 
Aspenstrom and Korsan-Bengsten judged five year survival rates in good 
risk patients on Dicumarol and placebo treatment. The groups had eighty-
four one hundredths and ninety-one one hundredths deaths per year, 
respectively, while the poor risk patients had rates of forty-seven one 
hundredths deaths per year in the Dicumarol group and thirty-four one 
hundredths deaths per year in the placebo group. The investigators felt 
that the patients in the poor risk group had decreased mortality in the 
second ~hrough the fifth year of the study. They concluded that good 
risk patients had little benefit from long term anticoagulant prophylaxis 
while high risk patients may be provided with protection in regard to 
thromboemboli. 
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Hensen (83), a co-author in the later Loeliger study, reported a 
double-blind study in a series of patients (only malignancies and atrial 
fibrillation patients were omitted fIOm the study). The patients were 
randomly placed in phenprocoumon and control groups. Among patients 
with some contraindication to anticoagulant therapy, the thrombotest 
values were kept from seven to thirteen per cent. Among the other 
patients, five to ten per cent thrombotest levels were used as 
therapeutic. Only six per cent of the thrombotest values done in the 
study were less than fifteen per cent. The differences in reinfarction 
rates were of high statistical significance in favor of the anticoagu-
lated group, while the mortality rate differences were not significant. 
Although Hensen concluded that the study demonstrated the benefit that 
can be expected from intensive long term anticoagulation therapy, and 
that negative or less impressive results most probably originate in the 
less intensive therapy, the fact that mortality is not appreciably altered 
and that reinfarction is such a difficult diagnosis allows us to question 
the impressiveness of this study. However, if his hypothesis is accepted, 
then a long acting drug, together with a thrombosis service in a medical 
center hospital, and close co-operation between the staff of this service 
with the attending physicians is absolutely necessary. 
Menwissen (84) reported the protocol and early results of his first 
year of a double-blind randomized study on the use of long term anti-
coagulant therapy after myocardial infarction. The long term period 
began three months after the myocardial infarction. One hundred forty 
patients were studied and no significant differences in the two groups 
were found. However, the trend was definitely toward prophylactic 
benefits with Marcoumar. 
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The Veteran's Administration Hospital co-operative study (11) 
which has been reiterated by Schnaper (85) was dore in the VA Hospitals 
throughout the country with central controls and carried out for seven 
years. Dicumarol and Coumadin were the agents used with evaluation of 
therapy by the one-stage Quick method at ten to twenty per cent of pro-
thrombin activity on a plasma dilution curve (twenty-six to thirty 
seconds). Eighty-one and six-tenths per cent of the values were in the 
therapeutic range of twenty-per cent or less, while eighty-nine and one-
tenth per cent were in the range of twenty-five per cent or less. This 
large study of seven hundred forty-seven patients was divided into compara-
ble groups by the sealed envelope technique. The difference in mortality 
rates were statistically significant in patients below the age of fifty. 
five years. Protection was afforded to all age groups to recurrent myo-
cardial infarction with high statistical significance. Bleeding occurred 
in over fifty per cent of the treated group at some tL~e during the 
therapy. There were three fatalities. 
The fact that the study was not double-blind is a deterrent, and in 
spite of the favorable results, the incidence of bleeding, even in minor 
episodes, was extremely high. The results are more favorable than many 
similar studies. However, since the investigations were carried out in 
many different hospitals, even though the protocol was the same, the many 
different observers may cause inconsistencies and possible bias. 
The study by Lovell and his associates was reported on three occa-
sions (10, 86, 87). The patients were divided randomly into three groups: 
the intermittent heparin group, the oral therapy group, and the group on 
L~adequate dosages of oral anticoagulants. After one year of therapy, 
there was no indication that the heparin therapy would prove more 
beneficial than phenprocoumon therapy in terms of mortality. In the 
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second report, there was no significant difference in the non-fatal re-
current infarction rate in the three groups. 
In the final report of the study, the number of patients had in-
creased to four hundred twelve, randomly allocated to one of the three 
groups. The range of therapy was fifteen per cent to thirty per cent 
of normal prothrombin activity. The sur~ival rates revealed no differ-
ences between the groups treated with low dosage phenprocoumon and 
heparin regimens. For men aged fifty-five years and under, but not for 
older men, the survival rate of the high dosage group was better than 
that of the low dosage group for the first t"i>V'O years. The authors 
acknowledged the difficulties in the conduction of these studies on the 
basis of insufficient numbers of patients. Lovell was very dogmatic in 
his belief that the value of the study should be based on improvements 
in mortality rates, since this is the important end factor, rather than 
upon improvement of reinfarction and other cardiovascular complication 
rates. It must be remembered that anticoagulation, if of value, is a 
prophylactic measure and not a cure. 
One other observation may be inferred from Lovell's study. If 
anticoagulant drugs are administered at all, oral admL~istration is as 
effective and much less inconvenient than the parenteral drug. 
In addition to the Lovell study, only two other studies have been 
reviewed with heparin being used intermittently for myocardial infarctions 
for long periods of time. In the study by Hughes and his associates (SS), 
heparin was injected in one hundred to two hundred milligram dosages sue-
I 
cutaneously every three days in fifty-three patients while I Coumadin was 
I 
used in fifty-one patients. In comparing the results, thei heparin group 
" 
did better in both mortality and reinfarction rates. The l!>t udy also 
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cor£irmed the feasibility and practicability of long term heparin 
therapy. Griffth (89) used heparin with favorable results, but no 
control group was used. 
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CONCLUSION 
~~ny studies which are in general disagreement have been re-
viewed. No physician has discovered the ideal treatment for myocardial 
infarction, although some feel that long term anticoagulant therapy ap-
proaches it. Each investigator recommends the use of anticoagulants for 
a certain patient. Unfortunately, no two studies seem to agree on which 
patient. 
The evaluation of long term anticoagulation after myocardial in-
farction has been, and will be, extremely difficult because of the 
multitude of variables in each patient~ There seems to be no hope for 
a study done so well that there would or could be a definite conclusion. 
However, the studies have shown a trend toward better results with the 
use of long term anticoagulant treatment. Whether this is the result of 
bias is not definitely known. 
If one intends to anticoagulate his patients on a long term basis 
following myocardial infarction, then it is imperative that the patient 
be reliable and co-operative. A physician must adopt the use of one 
drug and learn its actions well~ The laboratory control is apparently 
very important; therefore, the laboratory performing the studies must be 
able to produce consistent results with one of the tests. Thrombotest 
and the prothrombin proconvertin determinations seem to be the most 
reliable; however, in this country, the one-stage Quick test has been 
used almost exclusively. 
The treatment of the post~yocardial infarction patient may center 
about his anticoagulant therapy, but it is more imperative to treat com-
plications such as congestive heart failure with the appropriate measures 
than to do a Stat. prothrombin time. 
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There seems to be no excuse for a physician to use long term anti-
coagulant therapy if he does not have the facilities to control the 
therapy. Good medical center control would be ideal, and if this is not 
available, the patient would have less over-all risk by withholding the 
long term therapy. 
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